<DOC>
	<DOCNO>NCT00603044</DOCNO>
	<brief_summary>The purpose research find nasal spray ( fluticasone furoate ) , sometimes give child obstructive sleep apnea syndrome ( OSAS ) , work certain cell within child 's adenoid . We hypothesize intranasal steroid lead upregulation T regulatory cell adenoid tissue child OSAS . This result local reduction inflammation edema explain improvement OSAS .</brief_summary>
	<brief_title>Mechanism Action Fluticasone Furoate Childhood Obstructive Sleep Apnea Syndrome</brief_title>
	<detailed_description>The objective determine effect intranasal corticosteroid therapy T-regulatory cell inflammatory cytokine adenoid tissue child obstructive sleep apnea syndrome.Children randomize either treatment treatment fluticasone furoate nasal spray , 55 Î¼g/nostril daily , 2 week adenotonsillectomy . Adenoid tissue obtain time procedure .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Age : 2 12 year Polysomnogram result show AHI &gt; 5/hr irrespective saturation No significant medical problem except well control asthma No chronic medication intake except bronchodilator leukotriene receptor antagonists No systemic steroid within past month No intranasal steroid within past 2 week Patients OSAS overweight ( BMI &gt; 95th percentile age ) neurological craniofacial abnormality tend OSAS related factor per se . Females specify age group already first period .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>